Lisata Therapeutics (LSTA) Competitors $2.32 -0.03 (-1.28%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.35 +0.03 (+1.08%) As of 08/29/2025 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LSTA vs. ATRA, ORMP, IMUX, OVID, WHWK, QNCX, LIMN, JMAC, PYXS, and VXRTShould you be buying Lisata Therapeutics stock or one of its competitors? The main competitors of Lisata Therapeutics include Atara Biotherapeutics (ATRA), Oramed Pharmaceuticals (ORMP), Immunic (IMUX), Ovid Therapeutics (OVID), Whitehawk Therapeutics (WHWK), Quince Therapeutics (QNCX), Liminatus Pharma (LIMN), Maxpro Capital Acquisition (JMAC), Pyxis Oncology (PYXS), and Vaxart (VXRT). These companies are all part of the "pharmaceutical products" industry. Lisata Therapeutics vs. Its Competitors Atara Biotherapeutics Oramed Pharmaceuticals Immunic Ovid Therapeutics Whitehawk Therapeutics Quince Therapeutics Liminatus Pharma Maxpro Capital Acquisition Pyxis Oncology Vaxart Lisata Therapeutics (NASDAQ:LSTA) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability. Which has more risk & volatility, LSTA or ATRA? Lisata Therapeutics has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 0.22, meaning that its stock price is 78% less volatile than the S&P 500. Does the media favor LSTA or ATRA? In the previous week, Lisata Therapeutics had 1 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 2 mentions for Lisata Therapeutics and 1 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 1.48 beat Lisata Therapeutics' score of 1.06 indicating that Atara Biotherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Lisata Therapeutics Positive Atara Biotherapeutics Positive Do institutionals & insiders have more ownership in LSTA or ATRA? 8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 9.1% of Lisata Therapeutics shares are held by insiders. Comparatively, 4.0% of Atara Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is LSTA or ATRA more profitable? Atara Biotherapeutics has a net margin of 3.07% compared to Lisata Therapeutics' net margin of 0.00%. Atara Biotherapeutics' return on equity of -8.34% beat Lisata Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lisata TherapeuticsN/A -69.68% -59.44% Atara Biotherapeutics 3.07%-8.34%6.61% Do analysts recommend LSTA or ATRA? Lisata Therapeutics presently has a consensus price target of $23.50, suggesting a potential upside of 912.93%. Atara Biotherapeutics has a consensus price target of $21.00, suggesting a potential upside of 74.27%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Lisata Therapeutics is more favorable than Atara Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lisata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Atara Biotherapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.80 Which has preferable earnings and valuation, LSTA or ATRA? Lisata Therapeutics has higher earnings, but lower revenue than Atara Biotherapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLisata Therapeutics$1M20.32-$19.99M-$2.23-1.04Atara Biotherapeutics$128.94M0.66-$85.40M-$0.43-28.02 SummaryLisata Therapeutics and Atara Biotherapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Lisata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LSTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LSTA vs. The Competition Export to ExcelMetricLisata TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.31M$3.08B$5.71B$9.77BDividend YieldN/A2.28%6.66%4.48%P/E Ratio-1.0420.7883.2526.60Price / Sales20.32397.07538.85112.37Price / CashN/A43.5325.6628.92Price / Book0.669.7810.646.08Net Income-$19.99M-$54.01M$3.27B$265.93M7 Day Performance-10.42%-0.88%0.40%0.17%1 Month Performance-6.45%7.72%7.31%3.90%1 Year Performance-18.31%7.03%46.58%19.67% Lisata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LSTALisata Therapeutics2.3274 of 5 stars$2.32-1.3%$23.50+912.9%-18.3%$20.31M$1M-1.0430Positive NewsATRAAtara Biotherapeutics4.5257 of 5 stars$12.58+2.7%$21.00+67.0%+58.6%$88.28M$128.94M-29.24330Positive NewsORMPOramed Pharmaceuticals0.917 of 5 stars$2.13-1.8%N/A-7.9%$87.33M$1.34M-6.0910News CoverageIMUXImmunic2.6021 of 5 stars$0.88+0.3%$7.50+753.2%-45.7%$86.71MN/A-0.7170Positive NewsOVIDOvid Therapeutics4.1254 of 5 stars$1.21+6.1%$3.10+156.4%+13.3%$85.97M$570K-2.2860Analyst RevisionHigh Trading VolumeWHWKWhitehawk TherapeuticsN/A$1.82+7.1%N/AN/A$85.78M$25.98M-30.3340Positive NewsQNCXQuince Therapeutics3.8715 of 5 stars$1.59+0.6%$8.14+412.1%+131.5%$85.40MN/A-1.4660Positive NewsAnalyst UpgradeLIMNLiminatus PharmaN/A$3.28-3.5%N/AN/A$85.31MN/A0.00N/ANews CoverageAnalyst UpgradeGap DownJMACMaxpro Capital AcquisitionN/A$6.33+4.7%N/A+3,173.7%$85.00MN/A0.002,021News CoveragePYXSPyxis Oncology2.059 of 5 stars$1.37-1.8%$8.67+534.9%-66.2%$84.66M$16.15M-0.8560VXRTVaxart2.3961 of 5 stars$0.36+1.0%$2.00+460.4%-55.0%$81.70M$47.40M-1.32120News CoverageGap Up Related Companies and Tools Related Companies Atara Biotherapeutics Competitors Oramed Pharmaceuticals Competitors Immunic Competitors Ovid Therapeutics Competitors Whitehawk Therapeutics Competitors Quince Therapeutics Competitors Liminatus Pharma Competitors Maxpro Capital Acquisition Competitors Pyxis Oncology Competitors Vaxart Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LSTA) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lisata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lisata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LSTA Stock Alerts